17 December 2010
Cercle de l'Union Interalliée
- Dr François Meyer, Director of the medical evaluation, economic and public health to the High Authority for Health (HAS)
- Sylvain Forget, Director France of Swedish Orphan International (SOI)
At a time when big pharma challenge the blockbuster business model and opt for new growth strategies it appears opportune to make a focus on one of these new strategic options of promoting orphan or pediatric medicine .
To shed light on these recent business models that have developed in the context of specific regulations, the AHP has requested the testimony of two professional experts of these issues.
Our two speakers will present the regulatory and business issues related to orphan and pediatric medicines.